PCMO (Public CDMO for Microbial-based Vaccines, Director Min Cho) and MirimGENE Co., Ltd. (CEO Mirim Jin) are co-developing a ' Recombinant protein therapy for Tuberculosis' based on the innovative drug platform targeting WARS1(Tryptophanyl- tRNA synthetase 1) and announced this on July 16. 

source: https://www.yakup.com/news/index.html?mode=view&pmode=&cat=&cat2=&nid=296923&num_start=0&csearch_word=%EB%AF%B8%EB%A6%BC%EC%A7%84&csearch_type=&cs_scope=

Releated article: http://www.hitnews.co.kr/news/articleView.html?idxno=56132